Estimated Time to Complete Activity: 15 minutes

Statement of Need
Prostate cancer will account for more than 27,300 deaths in the United States during 2009, making it the second leading cause of cancer death in men. Most cases of prostate cancer are identified while the disease is still in the localized stage and is potentially curable with local radiotherapy or surgery; however, 4% of cases are identified at the advanced stage, which remains incurable despite recent advances in first- and second-line therapies. Androgen deprivation therapy (ADT) is typically used as an initial treatment for advanced prostate cancer. Although ADT can be very successful at slowing the progression of prostate cancer, in most patients, the cancer will become refractory to the hormone therapy within 3 years, necessitating the development of effective second-line treatments. Treatment with docetaxel-based chemotherapy, the current standard of care, can provide a modest survival advantage for patients with castration-resistant prostate cancer (CRPC).

Recent research advances and promising clinical outcomes support the application of immunotherapeutics as an additional treatment option for patients with CRPC. Several types of cancer immunotherapies have been developed for the treatment of prostate cancer, including dendritic cell–based, tumor cell–based, and viral vector–based vaccines. This program will update participants on the latest results from clinical trials that are investigating the safety and efficacy of novel, cancer vaccine immunotherapy for the treatment of advanced prostate cancer.

Target Audience
This activity is intended for medical oncologists, surgical oncologists, physician assistants, and other healthcare professionals interested in the treatment of patients with advanced prostate cancer.

Educational Objective
Upon completion of this activity, participants will be able to

1. Evaluate recent data from clinical trials that are investigating the use of cancer vaccines for the treatment of CRPC.

Method of Participation
This activity can be accessed using an iPhone^® or iPod touch^® and will be a featured program on the CBCE CME app, which may be downloaded from the Apple^® App Store. The activity will also be available on www.thecbce.com.

Accreditation
Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The CBCE designates this educational activity for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of .25 hour of Category 1 credit for completing this program.

CBCE CME App Credit Instructions
Successful completion of this activity includes the following:

• Complete the online posttest and score 70% or above.
• Complete the online Evaluation and Request for Credit Form.

Participants will receive their certificates via e-mail 4-6 weeks after submission of the online Evaluation and Request for Credit.

CBCE Website Credit Instructions
Successful completion of this activity includes the following:

• Score 70% or above on the posttest.
• Complete the Evaluation and Request for Credit Form.
• Fax the completed posttest and form to the CBCE, (214) 260-0509.

Participants will receive their certificate 4-6 weeks after the CBCE receives their posttest and form.

Educational Inquiries
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, TX 75063; Phone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.

Disclaimer
This activity in its current version is not commercially supported.

The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this program.

Disclosure of Unlabled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the latest edition of the Physicians’ Desk Reference.

Disclosure of Financial Relationships With Any Commercial Interest
As a provider accredited by the ACCME, it is the policy of the CBCE to require that everyone who is in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest, and identify and resolve all conflicts of interest prior to the educational activity. The CBCE defines “relevant financial relationships” as any amount occurring within the past 12 months.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honorarium, ownership interest (eg, stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. The CBCE considers relationships of the person involved in the educational activity to include financial relationships of a spouse or partner.

Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of or responsibility for the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship, participants must be informed that no relevant financial relationship exists.

Disclosure of Potential Conflicts of Interest
The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE activities. Identified conflicts of interest are thoroughly evaluated for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations. The CBCE is committed to providing participants with high-quality, unbiased, and state-of-the-art education.

The following faculty reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process:

E. David Crawford, MD
Advisory Board
AstraZeneca Pharmaceuticals LP
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc.
Poniard Pharmaceuticals, Inc.
sanofi-aventis
Soar BioDynamics, Ltd.
Grant/Research Support
Æterna Zentaris Inc.
Bostwick Laboratories, Inc.
Cancer Treatment Centers of America
EDAP TMS
Eigen Inc.
Endocare, Inc.
Ferring Pharmaceuticals
Galil Medical
Gen-Probe Incorporated
National Institutes of Health/National Cancer Institute
Oncura
Volunteer Work
Prostate Conditions Education Council
Us TOO

Institutional Disclosure
The CBCE receives educational grants from the pharmaceutical industry and other commercial sources. This activity in its current version is not commercially supported.

Staff Disclosure
The CBCE staff have declared they have no financial relationships that require disclosure.